Cyclooxygenase 2 (COX2) and Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Are Stage-Dependent Prognostic Markers of Malignant Melanoma
Table 1
COX2 and PPARG expression analysis of skin tumors using TMA-1.
Tumor entity
Cytoplasmic COX2 immunoreactivity
Nuclear PPARG immunoreactivity
analyzable
0 ()
1+ ()
2+ ()
3+ ()
analyzable
0 ()
1+ ()
2+ ()
3+ ()
TMA-1: total ()
186
34
86
54
12
212
143
50
19
0
.0003
Melanocytic lesions
Malignant melanoma
38
0
16
17
5
.02
41
21
8
12
0
.001
.01
Benign nevus
19
4
7
8
0
24
22
2
0
0
1.00
Epithelial tumors
Squamous cell carcinoma
30
3
10
11
6
.07
33
23
7
3
0
.001
.62
Basal cell carcinoma
31
7
16
7
1
33
11
21
1
0
.57
Connective tissue tumors
Kaposi sarcoma
15
6
8
1
0
.61
18
13
5
0
0
.13
1.00
Benign histiocytoma
16
8
7
1
0
22
19
1
2
0
.47
Capillary hemangioma
14
3
9
2
0
18
16
2
0
0
1.00
Appendix tumors
Benign sebaceous adenoma
23
3
13
7
0
23
18
4
1
0
1.00
's exact test (2-sided); bold face representing significant data. 's exact test (2-sided); association of COX2 and PPARG IHC within single tumor entities.